These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 1705571

  • 1. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM.
    J Immunol Methods; 1991 Feb 15; 136(2):221-37. PubMed ID: 1705571
    [Abstract] [Full Text] [Related]

  • 2. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM.
    Leukemia; 1993 Feb 15; 7(2):290-7. PubMed ID: 7678881
    [Abstract] [Full Text] [Related]

  • 3. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL.
    Blood; 1992 May 15; 79(10):2649-61. PubMed ID: 1375109
    [Abstract] [Full Text] [Related]

  • 4. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr 15; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

  • 5. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM.
    Leukemia; 1993 Feb 01; 7(2):298-309. PubMed ID: 7678882
    [Abstract] [Full Text] [Related]

  • 10. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Wendorf HR, Schneider EA, Covalciuc K, Johnson B, Clementson D, Irvin JD, Myers DE, Uckun FM.
    Leuk Lymphoma; 1996 Jun 01; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
    [Abstract] [Full Text] [Related]

  • 11. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.
    J Immunother; 2015 Sep 01; 38(7):299-305. PubMed ID: 26261894
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins.
    Lambert JM, Senter PD, Yau-Young A, Blättler WA, Goldmacher VS.
    J Biol Chem; 1985 Oct 05; 260(22):12035-41. PubMed ID: 4044586
    [Abstract] [Full Text] [Related]

  • 14. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE, Jun X, Clementson D, Donelson R, Sicheneder A, Hoffman N, Bell K, Sarquis M, Langlie MC, Turner N, Uckun FM.
    Leuk Lymphoma; 1997 Oct 05; 27(3-4):275-302. PubMed ID: 9402326
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
    Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM.
    Leuk Lymphoma; 1998 Sep 05; 31(1-2):143-9. PubMed ID: 9720724
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y, Yanishevski Y, Avramis VI, Ek O, Chelstrom LM, Gunther R, Myers DE, Irvin JD, Evans W, Uckun FM.
    Clin Cancer Res; 1996 Sep 05; 2(9):1533-42. PubMed ID: 9816330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.